Attorney Docket No.: OFI001-823298 Customer No. 054042

## **AMENDMENTS TO THE CLAIMS**

- 1. (Currently Amended) <u>A tablet Tablet</u> for oral administration that disintegrates quickly in the oral cavity in less than 30 seconds, comprising:
  - i) spray-dried mannitol of the crystalline form  $\alpha$  in a proportion of at least 59.5%;
  - active ingredient in a proportion below or equal to 10%, as a fine powder in which at least 90% in weight of the active ingredient has a particle size less than 100 μm;
  - iii) microcrystalline cellulose in a proportion from 10 to 18%, with an average particle size of approximately 50 μm where at least 99% in weight of microcrystalline cellulose has a particle size below 250 μm;
  - iv) sodium croscarmellose in a proportion from 1 to 4%; and
  - v) a lubricant agent in a proportion from 0.5 to 2% in weight, where, unless specified otherwise, the percentages are expressed in weight of the total weight of the tablet, wherein said tablet has a friability below 0.5%.
- 2. (Currently Amended) <u>The tablet Tablet</u> for oral administration according to claim 1, characterised in that it has a friability below 0.5% according to Ph. Eur. 2.9.7.
- 3. (Currently Amended) <u>The tablet Tablet</u> for oral administration according to claim 2, characterised in that it has a friability below 0.2% according to Ph. Eur. 2.9.7.
- 4. (Currently Amended) <u>The tablet Tablet</u> for oral administration according to claim 1, characterised in that it has an apparent density from 1.1 to 1.3 g/ml.
- 5. (Withdrawn) Tablet for oral administration according to claim 1, characterised in that it has a flavouring agent in a proportion from 0.5 to 2% in weight of the total weight of the tablet.

Attorney Docket No.: OFI001-823298

Customer No. 054042

6. (Withdrawn) Tablet for oral administration according to claim 5, characterised in that it

has an artificial sweetener in a proportion from 0.5 to 2% in weight of the total weight of

the tablet.

7. (Withdrawn) Tablet for oral administration according to claim 1, characterised in that it

has a humidity adsorbing agent in a proportion from 0.1 to 0.5% in weight of the total

weight of the tablet.

8. (Withdrawn) Tablet for oral administration according to claim 1, characterised in that it

has an anti-adherent agent in a proportion from 0.5 to 2% in weight of the total weight of

the tablet.

9. (Currently Amended) The tablet Tablet for oral administration according to claim 1.

characterised in that the proportion of insoluble elements is below 20% in weight of the

total weight of the tablet.

10. (Withdrawn) Tablet for oral administration according to any of previous claims,

characterised in that it has a round shape, flat, bevelled with a thickness from 1.8 to 2.2

mm.

11. (Withdrawn) Tablet for oral administration according to claim 10, characterised in that it

disintegrates quickly in the oral cavity in less than 20 seconds.

12. (Withdrawn) Process for obtaining a tablet for oral administration as defined in any of claims 1 to 11,

characterised in that it comprises the following steps:

i) Sieving and mixing the components except for the lubricant agent;

ii) Sieving the lubricant agent;

iii) Mixing of all the components; and

iv) Direct compression of the final mixture.

Attorney Docket No.: OFI001-823298 Customer No. 054042

13. (Withdrawn) Process for obtaining a tablet according to claim 12, characterised in that said final mixture has a flowability below or equal to 10 seconds according to Ph. Eur. 2.9.16.

14. (Withdrawn) Process for obtaining a tablet according to claim 12, characterised in that said final mixture has an ability to settle below or equal to 20 ml according to Ph. Eur. 2.9.15.